A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria:

A histologically or pathologically confirmed diagnosis of AML based on WHO classification with or without extramedullary disease except for central nervous system disease.
ECOG performance status ≤ 2
Left ventricular ejection fraction (LVEF) ≥ 50%
Female patients of childbearing potential must have a negative pregnancy test < 1 week prior to enrollment.
Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

Patients receiving any other investigational agents or immunotherapy
Patients who have received prior chemotherapy for AML with the exception of hydroxyurea or leukapheresis for leukocytosis; prior hypomethylating or immunomodulatory agents for MDS are allowed
Previous allo-HSCT of any kind
Active, uncontrolled infection including known hepatitis B or C
Active autoimmune disease and chronic inflammatory conditions requiring concurrent use of any systemic immunosuppressants or steroids.
History of any other active cancer diagnosis
Pregnant women
Known HIV-infected patients